Telomir Pharmaceuticals

Company snapshot

A novel treatment uniquely and selectively binds critical metals to interrupt enzyme function, returning cellular metals like Iron, copper, and zinc to homeostasis and turning off the underlying cause of cancer development and growth. By targeting specific classes of enzymes through its metal binding properties, Telomir 1 is believed to selectively affect the key processes that drive the concentra

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Telomir Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Telomir Pharmaceuticals.

1. May 23, 2026 Clinical update

   Zn-Telomir — Phase 2

View all clinical trial activity →

• What is Telomir Pharmaceuticals?

  Telomir Pharmaceuticals is a pharma organization headquartered in Tampa, USA. It trades on NYSE under ticker TELO. Primary therapeutic focus areas include Triple-Negative Breast Cancer (TNBC). NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) t

• Is Telomir Pharmaceuticals publicly traded?

  Yes. Telomir Pharmaceuticals is listed with ticker TELO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Telomir Pharmaceuticals develop or market?

  No drug profiles are currently linked to Telomir Pharmaceuticals. Pipeline programs may still list investigational assets.

• What are the latest developments for Telomir Pharmaceuticals?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Telomir Pharmaceuticals focus on?

  Telomir Pharmaceuticals focuses on Triple-Negative Breast Cancer (TNBC) based on our analysis of their pipeline programs and drug development activities.